Vinay Prasad reclaimed chief medical and scientific officer roles at the FDA’s Center for Biologics Evaluation and Research following his recent return. Eli Lilly appointed a former FDA cell and gene therapy official to lead policy efforts while Novo Nordisk named a new global research head amidst a large workforce reduction. Takeda recruited longtime Eli Lilly executive Rhonda Pacheco to oversee its U.S. business unit as Lilly reevaluates its UK Gateway Labs plans. These moves reflect significant leadership shifts influencing regulatory, research, and commercial strategies within the pharmaceutical and biotech sectors.